Periocular Gene Transfer For Retinal and Choroidal Diseases

Case ID:
C03994

C03994: Therapeutic for Ocular-related Diseases

Novelty:

A method of prophylactically or therapeutically treating an ocular disorder associated with abnormal neovascularization.

Value Proposition:

An overwhelming majority of the worlds population will experience some degree of vision loss in their lifetime, with the leading cause being ocular disorders. Ocular-related disorders, while often not life threatening, can be severely debilitating and require massive life-style changes. For many of the numerous ocular-disorders that exist, there are currently no effective therapeutic options. The few treatments that do exist can cause blind spot and almost all have been found to be equivalent to no treatment at all. This technology provides materials and methods for prophylactically and therapeutically treating ocular-related disorders associated with neovascularization. Advantages include:

• Highly selective in destroying endothelial cells associated with new vascular structures, without harming existing vasculature within the eye
• Applicable to a an array of ocular disease states
• Safe and effective

Technical Details:

Johns Hopkins researchers have developed a method of prophylactically and therapeutically treating ocular neovascularization by directly administering a therapeutic factor or nucleic acid sequence encoding a therapeutic factor to the eye to selectively induce apoptosis of endothelial cells associated with neovascularization. The therapeutic factor contains at least one inhibitor of angiogenesis and/or at least one neurotrophic factor to an ocular cell.

Looking for Partners:

To develop and commercialize the technology for the treatment of ocular-related disorders.

Stage of Development:

Pre-clinical

Data Availability:

In vitro data and in vivo data available

Publications/Associated Cases:

1. Hum Gene Ther. 2005 Apr;16(4):473-8
2. Gene Ther. 2003 Apr;10(8):637-46

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Selective Induction of Apoptosis to Treat Ocular Disease by Expression of PEDF DIV: Divisional United States 11/938,562 7,989,426 11/12/2007 8/2/2011 2/14/2023 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Mohit Ganguly
mgangul1@jh.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum